SureTrader
Interactive Brokers Advertisement
Home > Boards > Free Zone > Penny Trading - Technical > .00 stocks with high volume breakout above 50 day ma

nice board. NURO DD: Share Structure

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
ash111 Member Profile
Member Level 
Followed By 1,100
Posts 188,253
Boards Moderated 9
Alias Born 06/19/09
160x600 placeholder
ash111 Member Level  Thursday, 12/07/17 02:56:14 PM
Re: None
Post # of 28733 
nice board. NURO DD: Share Structure

Market Value1
$3,659,010
a/o Dec 06, 2017

Outstanding Shares
2,345,519
a/o Oct 13, 2017

Several Developments/Catalysts ahead:

1. Oct 31, 2017
NeuroMetrix Closed $3.5 Million Equity Offering

2. about $4m cash per last 10Q

3. Nov 29, 2017 NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,827,420. The patent covers novel technology that enhances Quell® device usability by improving performance for users that maintain an active lifestyle.

4. Quell® device, selling on Amazon. https://www.amazon.com/Quell-Wearable-Relief-Technology-Starter/dp/B075YVCLZT/ref=dp_ob_image_def#customerReviews
Third generation will be out in 2018

5. Insiders 100% buys, 11 transaction took place since July 2017- All purchase.

so many solid developments and so tiny market cap, trading about half cash on hand. a strong hold into 2018 if you ask me

several Catalysts:

Quell Opioid Reduction and Pain Relief in Patients with Cancer. Scripps Translational Science Institute, Scripps Health, San Diego, CA.
This randomized sham-controlled study is evaluating opioid use reduction in patients with various forms of cancer pain. The study is fully enrolled. Preliminary results are expected in Q4 ’17.
Efficacy of the Quell Wearable Device for Chronic Low Back Pain. Brigham and Women’s Hospital, Harvard Medical School, Boston, MA.
This randomized controlled study is evaluating pain relief and quality of life improvements in subjects with low back pain using Quell compared to control subjects on standard therapy. The study is 75% enrolled. Preliminary results are expected in Q4 ’17.
Prospective Validation of Quell Sleep/Wake Classification and Periodic Leg Movement Detection. Massachusetts General Hospital, Harvard Medical School, Boston, MA.
This study is comparing Quell sleep tracking to gold standard polysomnography. The study is 25% enrolled. Preliminary results are expected in Q4 ’17.


My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist